They made a study on a smaller number of pediatric IBD patients, suggesting that IL23R genes (rs10489628, rs10789229, and rs1343151) were more prevalent in patients with psoriasis after infliximab therapy than CD patients treated also by infliximab but who did not develop psoriasis [69]. The gene discussed is IL23R; the disease is inflammatory bowel disease.